Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
| Website | http://interpace.com |
| Ticker | IDXG |
| Revenue | $20.9 million |
| Employees | 122 (2 on RocketReach) |
| Founded | 1988 |
| Technologies |
JavaScript
,
HTML
,
PHP
+14 more
(view full list)
|
| Industry | Biotechnology Research, Other Healthcare Services, Molecular Diagnostics, Personalized Medicine |
| Keywords | Personalized Medicine, Early Diagnosis, Genetic Testing, Molecular Diagnostics, Cancer Diagnostics, Disease Diagnostics, Precision Oncology, Oncology Testing, Tissue Diagnostics, Molecular Pathology, Medical Diagnostics, Diagnostic Testing, Biomarker Discovery, Clinical Diagnostics, Diagnostic Biomarkers, Pathology Services, Therapeutic Applications, Healthcare Services, Value Chain Services |
| Competitors | Natera, Exact Sciences, Guardant Health, Myriad Genetics, Foundation Medicine, Invitae, Biodesix, Inc., Clarify Health Solutions, Genomic Health, PAML +27 more (view full list) |
Looking for a particular Interpace Biosciences employee's phone or email?
The Interpace Biosciences annual revenue was $20.9 million in 2026.
James Msc. is the Director, Business Development Biopharma Services West Coast and Asia - Interpace Pharma Solutions of Interpace Biosciences.
2 people are employed at Interpace Biosciences.